Sanara MedTech Inc.

SMTI

US79957L1008

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 01:30:00 01/06/2024 am IST			5-day change	1st Jan Change
29.7 ^USD	-1.62%		-4.19%	-27.74%

14/05	Transcript : Sanara MedTech Inc., Q1 2024 Earnings Call, May 14, 2024
13/05	Sanara MedTech Q1 Net Loss Widens, Revenue Increases -- Shares Down	MT

Sanara MedTech Inc. Elects J. Michael Carmena to Its Board of Directors

September 01, 2021 at 02:24 am IST

Sanara MedTech Inc. at its 2021 Annual Meeting of Shareholders held on September 30, 2021 elected J. Michael Carmena To the Company's Board of Directors, each to serve for a one-year term until the annual meeting of shareholders to be held in 2022 or until his or her successor is elected and qualified.

Latest news about Sanara MedTech Inc.

Transcript : Sanara MedTech Inc., Q1 2024 Earnings Call, May 14, 2024	14/05
Sanara MedTech Q1 Net Loss Widens, Revenue Increases -- Shares Down	13/05	MT
Sanara MedTech CEO Zachary Fleming Resigns	13/05	MT
Sanara MedTech Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	13/05	CI
Sanara MedTech Inc. Announces CEO Changes	13/05	CI
Sanara Medtech Inc. Announces $55 Million Debt Facility	18/04	CI
Sanara MedTech Appoints Jake Waldrop as Chief Operating Officer	05/04	MT
Sanara MedTech Inc. Announces Executive Changes, Effective April 15, 2024	05/04	CI
Cantor Fitzgerald Cuts Price Target on Sanara MedTech to $44 From $49, Maintains Overweight Rating	27/03	MT
Transcript : Sanara MedTech Inc., Q4 2023 Earnings Call, Mar 26, 2024	26/03
Earnings Flash (SMTI) SANARA MEDTECH Posts Q4 Revenue $17.7M, vs. Street Est of $16.5M	26/03	MT
Sanara MedTech Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	26/03	CI
Sanara MedTech Reports Higher Preliminary Q4 Revenue	23/02	MT
Sanara MedTech Inc. Announces Unaudited Preliminary Net Revenue Results for the Fourth Quarter and Full-Year 2023	22/02	CI
Sanara MedTech Secures Exclusive Licensing Deal with Tufts University for 18 Collagen Peptides	03/01	MT
Cantor Fitzgerald Adjusts Price Target on Sanara MedTech to $49 From $59, Maintains Overweight Rating	15/11	MT
Transcript : Sanara MedTech Inc., Q3 2023 Earnings Call, Nov 14, 2023	14/11
Sanara MedTech Q3 Loss Narrows, Revenue Rises; Shares Fall After Hours	14/11	MT
Earnings Flash (SMTI) SANARA MEDTECH Reports Q3 Revenue $16M, vs. Street Est of $18.8M	14/11	MT
Sanara MedTech Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	14/11	CI
Sanara MedTech Inc. Announces BIASURGE Advanced Surgical Solution Updates	10/23/10	CI
Transcript : Sanara MedTech Inc., Q2 2023 Earnings Call, Aug 15, 2023	15/23/15
Earnings Flash (SMTI) SANARA MEDTECH Reports Q2 Revenue $15.8M, vs. Street Est of $16.9M	15/23/15	MT
Sanara MedTech Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	15/23/15	CI
Sanara MedTech Acquires Selected Assets Related to Its Collagen Products Business	02/23/02	MT

Chart Sanara MedTech Inc.

Duration

Period

More charts

Company Profile

Sanara Medtech Inc. is a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skincare markets. It markets several products for surgical and chronic wound care applications and has multiple products in its pipeline. Its surgical products, CellerateRX Surgical, TEXAGEN, BiFORM, ACTIGEN, ALLOCYTE, ALLOCYTE Plus Advanced Viable Bone Matrix (ALLOCYTE Plus), BIASURGE, FORTIFY TRG Tissue Repair Graft (FORTIFY TRG), and FORTIFY FLOWABLE Extracellular Matrix (FORTIFY FLOWABLE) are used in a range of surgical specialties to help promote patient healing and reduce the risk of complications. CellerateRX Surgical products, TEXAGEN products, FORTIFY TRG and FORTIFY FLOWABLE are used in specialties, including cardiothoracic, colorectal, general surgery, hand, head and neck, high-risk obstetrics and gynecology, Mohs surgery, neurosurgery, and others.

Sector

Pharmaceuticals

Calendar

12/06/2024 - Annual General Meeting

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

29.7 USD

Average target price

44 USD

Spread / Average Target

+48.15%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
SANARA MEDTECH INC.	-27.74%	26Cr
ELI LILLY AND COMPANY	+40.73%	73TCr
NOVO NORDISK A/S	+32.83%	59TCr
JOHNSON & JOHNSON	-6.30%	35TCr
MERCK & CO., INC.	+15.15%	32TCr
ABBVIE INC.	+4.05%	28TCr
ASTRAZENECA PLC	+15.00%	24TCr
NOVARTIS AG	+9.78%	21TCr
ROCHE HOLDING AG	-5.52%	20TCr
AMGEN INC.	+6.17%	16TCr

Other Pharmaceuticals